Over-expression of the thrombin receptor (PAR-1) in the placenta in preeclampsia: A mechanism for the intersection of coagulation and inflammation

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 21, Issue 6, 2008, Pages 345-355

  Erez, Offer ^a,d   Romero, Roberto ^a,b,d   Kim, Sung Su ^a   Kim, Jung Sun ^a,b   Kim, Yeon Mee ^a,b   Wildman, Derek E ^a,b   Than, Nandor Gabor ^a   Mazaki Tovi, Shali ^a,b   Gotsch, Francesca ^a   Pineles, Beth ^a   Kusanovic, Juan Pedro ^a,b   Espinoza, Jimmy ^a,b   Mittal, Pooja ^a,b   Mazor, Moshe ^c   Hassan, Sonia S ^a,b   Kim, Chong Jai ^a,b  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^d HUTZEL HOSPITAL   (United States)

Author keywords

Immunohistochemistry; PAR 1; Preterm; Tethered ligand; Trophoblast; Villous infarct

Indexed keywords

PROTEINASE ACTIVATED RECEPTOR 1; THROMBIN RECEPTOR;

ADULT; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; DELIVERY; FEMALE; GESTATIONAL AGE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFLAMMATION; PLACENTA; PLACENTA VILLUS; PREECLAMPSIA; PREMATURE LABOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TROPHOBLAST;

ADULT; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INFLAMMATION; OBSTETRIC LABOR, PREMATURE; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; RECEPTOR, PAR-1; TROPHOBLASTS;

EID: 47349114249     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.1080/14767050802034859     Document Type: Article

References (143)

1. Brosens I, Renaer M. On the pathogenesis of placental infarcts in pre-eclampsia. J Obstet Gynaecol Br Commonw 1972;79:794-799.
2. Sikkema JM, Franx A, Bruinse HW, van der Wijk NG, de Valk HW, Nikkels PG. Placental pathology in early onset pre-eclampsia and intra-uterine growth restriction in women with and without thrombophilia. Placenta 2002;23:337-342.
3. Faye-Petersen OM, Heller DS, Joshi VV. Histologic lesions of the placenta: villi, fetal stem arteries, intervillous spcae and maternal arteries in decidua. The Handbook of Placental Pathology. 2nd ed. London: Taylor Francis; 2006. pp 53-79.
4. Benirschke K, Kaufmann P. Pathology of the human placenta. In: Benirschke K, Kaufmann P, editors. 4th ed. New York: Springer; 2000.
5. Kim YM, Bujold E, Chaiworapongsa T, Gomez R, Yoon BH, Thaler HT, Rotmensch S, Romero R. Failure of physiologic transformation of the spiral arteries in patients with preterm labor and intact membranes. Am J Obstet Gynecol 2003;189:1063-1069.
6. Moldenhauer JS, Stanek J, Warshak C, Khoury J, Sibai B. The frequency and severity of placental findings in women with preeclampsia are gestational age dependent. Am J Obstet Gynecol 2003;189:1173-1177.
7. Redline RW, Boyd T, Campbell V, Hyde S, Kaplan C, Khong TY, Prashner HR, Waters BL. Maternal vascular underperfusion: nosology and reproducibility of placental reaction patterns. Pediatr Dev Pathol 2004;7:237-249.
8. Redline RW, Heller D, Keating S, Kingdom J. Placental diagnostic criteria and clinical correlation - a workshop report. Placenta 2005;26(Suppl. A):S114-S117.
9. Schjetlein R, Haugen G, Wisloff F. Markers of intravascular coagulation and fibrinolysis in preeclampsia: association with intrauterine growth retardation. Acta Obstet Gynecol Scand 1997;76:541-546.
10. Cadroy Y, Grandjean H, Pichon J, Desprats R, Berrebi A, Fournie A, Boneu B. Evaluation of six markers of haemostatic system in normal pregnancy and pregnancy complicated by hypertension or pre-eclampsia. Br J Obstet Gynaecol 1993;100:416-420.
11. Chaiworapongsa T, Yoshimatsu J, Espinoza J, Kim YM, Berman S, Edwin S, Yoon BH, Romero R. Evidence of in vivo generation of thrombin in patients with small-for-gestational-age fetuses and pre-eclampsia. J Matern Fetal Neonatal Med 2002;11:362-367.
12. Stenberg PE, McEver RP, Shuman MA, Jacques YV, Bainton DF. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol 1985;101:880-886.
13. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391:591-594.
14. Furie B, Furie BC. Molecular and cellular biology of blood coagulation. N Engl J Med 1992;326:800-806.
15. Mann KG, Lorand L. Introduction: blood coagulation. Methods Enzymol 1993;222:1-10.
16. Dahlback B. Blood coagulation. Lancet 2000;355:1627-1632.
17. Nesheim M. Thrombin and fibrinolysis. Chest 2003;124:33S-39S.
18. Hattori R, Hamilton KK, Fugate RD, McEver RP, Sims PJ. Stimulated secretion of endothelial von Willebrand factor is accompanied by rapid redistribution to the cell surface of the intracellular granule membrane protein GMP-140. J Biol Chem 1989;264:7768-7771.
19. Lum H, Malik AB. Regulation of vascular endothelial barrier function. Am J Physiol 1994;267:L223-L241.
20. Cirino G, Cicala C, Bucci MR, Sorrentino L, Maraganore JM, Stone SR. Thrombin functions as an inflammatory mediator through activation of its receptor. J Exp Med 1996;183:821-827.
21. Bar-Shavit R, Kahn A, Wilner GD, Fenton JW. Monocyte chemotaxis: stimulation by specific exosite region in thrombin. Science 1983;220:728-731.
22. Bizios R, Lai L, Fenton JW, Malik AB. Thrombin-induced chemotaxis and aggregation of neutrophils. J Cell Physiol 1986;128:485-490.
23. Sonne O. The specific binding of thrombin to human polymorphonuclear leucocytes. Scand J Clin Lab Invest 1988;48:831-838.
24. Drake WT, Issekutz AC. A role for alpha-thrombin in polymorphonuclear leukocyte recruitment during inflammation. Semin Thromb Hemost 1992;18:333-340.
25. Drake WT, Lopes NN, Fenton JW, Issekutz AC. Thrombin enhancement of interleukin-1 and tumor necrosis factor-alpha induced polymorphonuclear leukocyte migration. Lab Invest 1992;67:617-627.
26. Naldini A, Carney DH, Bocci V, Klimpel KD, Asuncion M, Soares LE, Klimpel GR. Thrombin enhances T cell proliferative responses and cytokine production. Cell Immunol 1993;147:367-377.
27. Franchini M, Veneri D, Lippi G. Inflammation and hemostasis: a bidirectional interaction. Clin Lab 2007;53:63-67.
28. Dery O, Corvera CU, Steinhoff M, Bunnett NW. Proteinase-activated receptors: novel mechanisms of signaling by serine proteases. Am J Physiol 1998;274:C1429-C1452.
29. Coughlin SR. Protease-activated receptors and platelet function. Thromb Haemost 1999;82:353-356.
30. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000;407:258-264.
31. Coughlin SR. Protease-activated receptors in vascular biology. Thromb Haemost 2001;86:298-307.
32. Landis RC. Protease activated receptors: clinical relevance to hemostasis and inflammation. Hematol Oncol Clin North Am 2007;21:103-113.
33. Grand RJ, Turnell AS, Grabham PW. Cellular consequences of thrombin-receptor activation. Biochem J 1996;313(Pt 2):353-368.
34. O'Brien PJ, Molino M, Kahn M, Brass LF. Protease activated receptors: theme and variations. Oncogene 2001;20:1570-1581.
35. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 1999;103:879-887.
36. Hung DT, Vu TK, Wheaton VI, Ishii K, Coughlin SR. Cloned platelet thrombin receptor is necessary for thrombin-induced platelet activation. J Clin Invest 1992;89:1350-1353.
37. Naldini A, Carney DH, Pucci A, Pasquali A, Carraro F. Thrombin regulates the expression of proangiogenic cytokines via proteolytic activation of protease-activated receptor-1. Gen Pharmacol 2000;35:255-259.
38. Li T, He S. Induction of IL-6 release from human T cells by PAR-1 and PAR-2 agonists. Immunol Cell Biol 2006;84:461-466.
39. Li T, Wang H, He S. Induction of interleukin-6 release from monocytes by serine proteinases and its potential mechanisms. Scand J Immunol 2006;64:10-16.
40. Hirano K, Kanaide H. Role of protease-activated receptors in the vascular system. J Atheroscler Thromb 2003;10:211-225.
41. Duarte M, Kolev V, Soldi R, Kirov A, Graziani I, Oliveira SM, Kacer D, Friesel R, Maciag T, Prudovsky I. Thrombin induces rapid PAR1-mediated non-classical FGF1 release. Biochem Biophys Res Commun 2006;350:604-609.
42. Connolly AJ, Ishihara H, Kahn ML, Farese RV Jr, Coughlin SR. Role of the thrombin receptor in development and evidence for a second receptor. Nature 1996;381:516-519.
43. Darrow AL, Fung-Leung WP, Ye RD, Santulli RJ, Cheung WM, Derian CK, Burns CL, Damiano BP, Zhou L, Keenan CM, et al. Biological consequences of thrombin receptor deficiency in mice. Thromb Haemost 1996;76:860-866.
44. Major CD, Santulli RJ, Derian CK, Andrade-Gordon P. Extracellular mediators in atherosclerosis and thrombosis: lessons from thrombin receptor knockout mice. Arterioscler Thromb Vasc Biol 2003;23:931-939.
45. Even-Ram SC, Grisaru-Granovsky S, Pruss D, Maoz M, Salah Z, Yong-Jun Y, Bar-Shavit R. The pattern of expression of protease-activated receptors (PARs) during early trophoblast development. J Pathol 2003;200:47-52.
46. O'Brien PJ, Koi H, Parry S, Brass LF, Strauss JF III, Wang LP, Tomaszewski JE, Christenson LK. Thrombin receptors and protease-activated receptor-2 in human placentation: receptor activation mediates extravillous trophoblast invasion in vitro. Am J Pathol 2003;163:1245-1254.
47. Wang Y, Gu Y, Lucas MJ. Expression of thrombin receptors in endothelial cells and neutrophils from normal and preeclamptic pregnancies. J Clin Endocrinol Metab 2002;87:3728-3734.
48. Alexander GR, Himes JH, Kaufman RB, Mor J, Kogan M. A United States national reference for fetal growth. Obstet Gynecol 1996;87:163-168.
49. Richani K, Romero R, Kim YM, Cushenberry E, Soto E, Han YM, Espinoza J, Kim CJ. Tissue microarray: an effective high-throughput method to study the placenta for clinical and research purposes. J Matern Fetal Neonatal Med 2006;19:509-515.
50. de Boer K, ten Cate JW, Sturk A, Borm JJ, Treffers PE. Enhanced thrombin generation in normal and hypertensive pregnancy. Am J Obstet Gynecol 1989;160:95-100.
51. Reber G, Amiral J, de Moerloose P. Modified antithrombin III levels during normal pregnancy and relationship with prothrombin fragment F1 + 2 and thrombin-antithrombin complexes. Thromb Res 1998;91:45-47.
52. Reinthaller A, Mursch-Edlmayr G, Tatra G. Thrombin-antithrombin III complex levels in normal pregnancy with hypertensive disorders and after delivery. Br J Obstet Gynaecol 1990;97:506-510.
53. Uszynski M. Generation of thrombin in blood plasma of non-pregnant and pregnant women studied through concentration of thrombin-antithrombin III complexes. Eur J Obstet Gynecol Reprod Biol 1997;75:127-131.
54. Andersson T, Lorentzen B, Hogdahl H, Clausen T, Mowinckel MC, Abildgaard U. Thrombin-inhibitor complexes in the blood during and after delivery. Thromb Res 1996;82:109-117.
55. Hayashi M, Numaguchi M, Ohkubo N, Yaoi Y. Blood macrophage colony-stimulating factor and thrombin-antithrombin III complex concentrations in pregnancy and preeclampsia. Am J Med Sci 1998;315:251-257.
56. Hayashi M, Inoue T, Hoshimoto K, Negishi H, Ohkura T, Inaba N. Characterization of five marker levels of the hemostatic system and endothelial status in normotensive pregnancy and pre-eclampsia. Eur J Haematol 2002;69:297-302.
57. Kobayashi T, Terao T. Preeclampsia as chronic disseminated intravascular coagulation. Study of two parameters: thrombin-antithrombin III complex and D-dimers. Gynecol Obstet Invest 1987;24:170-178.
58. Kobayashi T, Tokunaga N, Sugimura M, Suzuki K, Kanayama N, Nishiguchi T, Terao T. Coagulation/fibrinolysis disorder in patients with severe preeclampsia. Semin Thromb Hemost 1999;25:451-454.
59. Kobayashi T, Sumimoto K, Tokunaga N, Sugimura M, Nishiguchi T, Kanayama N, Terao T. Coagulation index to distinguish severe preeclampsia from normal pregnancy. Semin Thromb Hemost 2002;28:495-500.
60. Schjetlein R, Abdelnoor M, Haugen G, Husby H, Sandset PM, Wisloff F. Hemostatic variables as independent predictors for fetal growth retardation in preeclampsia. Acta Obstet Gynecol Scand 1999;78:191-197.
61. VanWijk MJ, Boer K, Berckmans RJ, Meijers JC, van der Post JA, Sturk A, VanBavel E, Nieuwland R. Enhanced coagulation activation in preeclampsia: the role of APC resistance, microparticles and other plasma constituents. Thromb Haemost 2002;88:415-420.
62. Hayashi M, Ohkura T. Elevated levels of serum macrophage colony-stimulating factor in normotensive pregnancies complicated by intrauterine fetal growth restriction. Exp Hematol 2002;30:388-393.
63. Ballard HS, Marcus AJ. Primary and secondary platelet aggregation in uraemia. Scand J Haematol 1972;9:198-203.
64. Chaiworapongsa T, Espinoza J, Yoshimatsu J, Kim YM, Bujold E, Edwin S, Yoon BH, Romero R. Activation of coagulation system in preterm labor and preterm premature rupture of membranes. J Matern Fetal Neonatal Med 2002;11:368-373.
65. Elovitz MA, Baron J, Phillippe M. The role of thrombin in preterm parturition. Am J Obstet Gynecol 2001;185:1059-1063.
66. Rosen T, Kuczynski E, O'Neill LM, Funai EF, Lockwood CJ. Plasma levels of thrombin-antithrombin complexes predict preterm premature rupture of the fetal membranes. J Matern Fetal Med 2001;10:297-300.
67. Elovitz MA, Ascher-Landsberg J, Saunders T, Phillippe M. The mechanisms underlying the stimulatory effects of thrombin on myometrial smooth muscle. Am J Obstet Gynecol 2000;183:674-681.
68. Elovitz MA, Saunders T, Ascher-Landsberg J, Phillippe M. Effects of thrombin on myometrial contractions in vitro and in vivo. Am J Obstet Gynecol 2000;183:799-804.
69. Rosen T, Schatz F, Kuczynski E, Lam H, Koo AB, Lockwood CJ. Thrombin-enhanced matrix metalloproteinase-1 expression: a mechanism linking placental abruption with premature rupture of the membranes. J Matern Fetal Neonatal Med 2002;11:11-17.
70. Stephenson CD, Lockwood CJ, Ma Y, Guller S. Thrombin-dependent regulation of matrix metalloproteinase (MMP)- 9 levels in human fetal membranes. J Matern Fetal Neonatal Med 2005;18:17-22.
71. Sacks GP, Studena K, Sargent K, Redman CW. Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. Am J Obstet Gynecol 1998;179:80-86.
72. Luppi P, Haluszczak C, Trucco M, Deloia JA. Normal pregnancy is associated with peripheral leukocyte activation. Am J Reprod Immunol 2002;47:72-81.
73. Richani K, Soto E, Romero R, Espinoza J, Chaiworapongsa T, Nien JK, Edwin S, Kim YM, Hong JS, Mazor M. Normal pregnancy is characterized by systemic activation of the complement system. J Matern Fetal Neonatal Med 2005;17:239-245.
74. Benyo DF, Smarason A, Redman CW, Sims C, Conrad KP. Expression of inflammatory cytokines in placentas from women with preeclampsia. J Clin Endocrinol Metab 2001;86:2505-2512.
75. Keelan JA, Mitchell MD. Placental cytokines and preeclampsia. Front Biosci 2007;12:2706-2727.
76. Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999;180:499-506.
77. Gratacos E. Lipid-mediated endothelial dysfunction: a common factor to preeclampsia and chronic vascular disease. Eur J Obstet Gynecol Reprod Biol 2000;92:63-66.
78. Carr DB, McDonald GB, Brateng D, Desai M, Thach CT, Easterling TR. The relationship between hemodynamics and inflammatory activation in women at risk for preeclampsia. Obstet Gynecol 2001;98:1109-1116.
79. Wolf M, Kettyle E, Sandler L, Ecker JL, Roberts J, Thadhani R. Obesity and preeclampsia: the potential role of inflammation. Obstet Gynecol 2001;98:757-762.
80. Redman CW, Sargent IL. The pathogenesis of pre-eclampsia. Gynecol Obstet Fertil 2001;29:518-522.
81. Chaiworapongsa T, Gervasi MT, Refuerzo J, Espinoza J, Yoshimatsu J, Berman S, Romero R. Maternal lymphocyte subpopulations (CD45RA+ and CD45RO+) in preeclampsia. Am J Obstet Gynecol 2002;187:889-893.
82. Redman CW, Sargent IL. Pre-eclampsia, the placenta and the maternal systemic inflammatory response - a review. Placenta 2003;24(Suppl. A):S21-S27.
83. Sargent IL, Germain SJ, Sacks GP, Kumar S, Redman CW. Trophoblast deportation and the maternal inflammatory response in pre-eclampsia. J Reprod Immunol 2003;59:153-160.
84. Saito S, Sakai M. Th1/Th2 balance in preeclampsia. J Reprod Immunol 2003;59:161-173.
85. Freeman DJ, McManus F, Brown EA, Cherry L, Norrie J, Ramsay JE, Clark P, Walker ID, Sattar N, Greer IA. Shortand long-term changes in plasma inflammatory markers associated with preeclampsia. Hypertension 2004;44:708-714.
86. Todros T, Bontempo S, Piccoli E, Ietta F, Romagnoli R, Biolcati M, Castellucci M, Paulesu L. Increased levels of macrophage migration inhibitory factor (MIF) in preeclampsia. Eur J Obstet Gynecol Reprod Biol 2005;123:162-166.
87. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 2005;308:1592-1594.
88. Luppi P, Deloia JA. Monocytes of preeclamptic women spontaneously synthesize pro-inflammatory cytokines. Clin Immunol 2006;118:268-275.
89. Borzychowski AM, Sargent IL, Redman CW. Inflammation and pre-eclampsia. Semin Fetal Neonatal Med 2006;11:309-316.
90. Elovitz MA. Anti-inflammatory interventions in pregnancy: now and the future. Semin Fetal Neonatal Med 2006;11:327-332.
91. Luppi P, Tse H, Lain KY, Markovic N, Piganelli JD, Deloia JA. Preeclampsia activates circulating immune cells with engagement of the NF-kappaB pathway. Am J Reprod Immunol 2006;56:135-144.
92. Gervasi MT, Chaiworapongsa T, Pacora P, Naccasha N, Yoon BH, Maymon E, Romero R. Phenotypic and metabolic characteristics of monocytes and granulocytes in preeclampsia. Am J Obstet Gynecol 2001;185:792-797.
93. Rinehart BK, Terrone DA, Lagoo-Deenadayalan S, Barber WH, Hale EA, Martin JN Jr, Bennett WA. Expression of the placental cytokines tumor necrosis factor alpha, interleukin 1beta, and interleukin 10 is increased in preeclampsia. Am J Obstet Gynecol 1999;181:915-920.
94. Sabatier F, Bretelle F, D'Ercole C, Boubli L, Sampol J, Dignat-George F. Neutrophil activation in preeclampsia and isolated intrauterine growth restriction. Am J Obstet Gynecol 2000;183:1558-1563.
95. Selvaggi L, Lucivero G, Iannone A, dell'Osso A, Loverro G, Antonaci S, Bonomo L, Bettocchi S. Analysis of mononuclear cell subsets in pregnancies with intrauterine growth retardation. Evidence of chronic B-lymphocyte activation. J Perinat Med 1983;11:213-217.
96. Bozzola M, Chirico G, Chiara A, Gasparoni A, Schimpff RM. Serum growth-promoting activity in human newborns. Relationship of thymidine activity with birth weight and the length of gestation. Acta Paediatr Scand 1985;74:534-538.
97. Johnston TA, Greer IA, Dawes J, Calder AA. Neutrophil activation in small for gestational age pregnancies. Br J Obstet Gynaecol 1991;98:105-106.
98. Girardi G, Yarilin D, Thurman JM, Holers VM, Salmon JE. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med 2006;203:2165-2175.
99. Campbell MK, Challis JR, DaSilva O, Bocking AD. A cohort study found that white blood cell count and endocrine markers predicted preterm birth in symptomatic women. J Clin Epidemiol 2005;58:304-310.
100. Romero R, Ceska M, Avila C, Mazor M, Behnke E, Lindley I. Neutrophil attractant/activating peptide-1/interleukin-8 in term and preterm parturition. Am J Obstet Gynecol 1991;165:813-820.
101. Bry K, Hallman M. Prostaglandins, inflammation, and preterm labor. J Perinatol 1989;9:60-65.
102. Gennaro S, Fehder WP, Cnaan A, York R, Campbell DE, Gallagher PR, Douglas SD. Immune responses in mothers of term and preterm very-low-birth-weight infants. Clin Diagn Lab Immunol 1997;4:565-571.
103. Soto E, Romero R, Richani K, Espinoza J, Nien JK, Chaiworapongsa T, Santolaya-Forgas J, Edwin SS, Mazor M. Anaphylatoxins in preterm and term labor. J Perinat Med 2005;33:306-313.
104. Gervasi MT, Chaiworapongsa T, Naccasha N, Blackwell S, Yoon BH, Maymon E, Romero R. Phenotypic and metabolic characteristics of maternal monocytes and granulocytes in preterm labor with intact membranes. Am J Obstet Gynecol 2001;185:1124-1129.
105. Bahar AM, Ghalib HW, Moosa RA, Zaki ZM, Thomas C, Nabri OA. Maternal serum interleukin-6, interleukin-8, tumor necrosis factor-alpha and interferon-gamma in preterm labor. Acta Obstet Gynecol Scand 2003;82:543-549.
106. Vogel I, Grove J, Thorsen P, Moestrup SK, Uldbjerg N, Moller HJ. Preterm delivery predicted by soluble CD163 and CRP in women with symptoms of preterm delivery. BJOG 2005;112:737-742.
107. Sorensen TK, Dempsey JC, Xiao R, Frederick IO, Luthy DA, Williams MA. Maternal asthma and risk of preterm delivery. Ann Epidemiol 2003;13:267-272.
108. Sendag F, Itil IM, Terek MC, Yilmaz H. The changes of circulating lymphocyte sub-populations in women with preterm labour: a case-controlled study. Aust N Z J Obstet Gynaecol 2002;42:358-361.
109. Sozmen S, Mungan T, Micozkadioglu SD, Tapisiz OL. Predictive value of maternal serum and vaginal interleukin-6 levels in preterm labor. J Soc Gynecol Investig 2005;12:e1-e6.
110. Gervasi MT, Chaiworapongsa T, Naccasha N, Pacora P, Berman S, Maymon E, Kim JC, Kim YM, Yoshimatsu J, Espinoza J, et al. Maternal intravascular inflammation in preterm premature rupture of membranes. J Matern Fetal Neonatal Med 2002;11:171-175.
111. Helmig BR, Romero R, Espinoza J, Chaiworapongsa T, Bujold E, Gomez R, Ohlsson K, Uldbjerg N. Neutrophil elastase and secretory leukocyte protease inhibitor in prelabor rupture of membranes, parturition and intraamniotic infection. J Matern Fetal Neonatal Med 2002;12:237-246.
112. Bonnar J, Redman CW, Denson KW. The role of coagulation and fibrinolysis in preeclampsia. Perspect Nephrol Hypertens 1976;5:85-93.
113. Tanjung MT, Siddik HD, Hariman H, Koh SC. Coagulation and fibrinolysis in preeclampsia and neonates. Clin Appl Thromb Hemost 2005;11:467-473.
114. Ellis CA, Malik AB, Gilchrist A, Hamm H, Sandoval R, Voyno-Yasenetskaya T, Tiruppathi C. Thrombin induces proteinase-activated receptor-1 gene expression in endothelial cells via activation of Gi-linked Ras/mitogen- activated protein kinase pathway. J Biol Chem 1999;274:13718-13727.
115. Mbebi C, Rohn T, Doyennette MA, Chevessier F, Jandrot-Perrus M, Hantai D, Verdiere-Sahuque M. Thrombin receptor induction by injury-related factors in human skeletal muscle cells. Exp Cell Res 2001;263:77-87.
116. Dugina TN, Kiseleva EV, Chistov IV, Umarova BA, Strukova SM. Receptors of the PAR family as a link between blood coagulation and inflammation. Biochemistry (Mosc.) 2002;67:65-74.
117. Dugina TN, Kiseleva EV, Glusa E, Strukova SM. Activation of mast cells induced by agonists of proteinase-activated receptors under normal conditions and during acute inflammation in rats. Eur J Pharmacol 2003;471:141-147.
118. Asokananthan N, Graham PT, Fink J, Knight DA, Bakker AJ, McWilliam AS, Thompson PJ, Stewart GA. Activation of protease-activated receptor (PAR)-1, PAR-2, and PAR-4 stimulates IL-6, IL-8, and prostaglandin E2 release from human respiratory epithelial cells. J Immunol 2002;168:3577-3585.
119. Ma L, Perini R, McKnight W, Dicay M, Klein A, Hollenberg MD, Wallace JL. Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc Natl Acad Sci USA 2005;102:216-220.
120. Arisato T, Sarker KP, Kawahara K, Nakata M, Hashiguchi T, Osame M, Kitajima I, Maruyama I. The agonist of the protease-activated receptor-1 (PAR) but not PAR3 mimics thrombin-induced vascular endothelial growth factor release in human smooth muscle cells. Cell Mol Life Sci 2003;60:1716-1724.
121. Cunningham MA, Rondeau E, Chen X, Coughlin SR, Holdsworth SR, Tipping PG. Protease-activated receptor 1 mediates thrombin-dependent, cell-mediated renal inflammation in crescentic glomerulonephritis. J Exp Med 2000;191:455-462.
122. Griffin CT, Srinivasan Y, Zheng YW, Huang W, Coughlin SR. A role for thrombin receptor signaling in endothelial cells during embryonic development. Science 2001;293:1666-1670.
123. Chan B, Merchan JR, Kale S, Sukhatme VP. Antiangiogenic property of human thrombin. Microvasc Res 2003;66:1-14.
124. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649-658.
125. Wolf M, Hubel CA, Lam C, Sampson M, Ecker JL, Ness RB, Rajakumar A, Daftary A, Shakir AS, Seely EW, et al. Preeclampsia and future cardiovascular disease: potential role of altered angiogenesis and insulin resistance. J Clin Endocrinol Metab 2004;89:6239-6243.
126. Bdolah Y, Sukhatme VP, Karumanchi SA. Angiogenic imbalance in the pathophysiology of preeclampsia: newer insights. Semin Nephrol 2004;24:548-556.
127. Karumanchi SA, Bdolah Y. Hypoxia and sFlt-1 in preeclampsia: the "chicken-and-egg" question. Endocrinology 2004;145:4835-4837.
128. Davison JM, Homuth V, Jeyabalan A, Conrad KP, Karumanchi SA, Quaggin S, Dechend R, Luft FC. New aspects in the pathophysiology of preeclampsia. J Am Soc Nephrol 2004;15:2440-2448.
129. Thadhani R, Ecker JL, Mutter WP, Wolf M, Smirnakis KV, Sukhatme VP, Levine RJ, Karumanchi SA. Insulin resistance and alterations in angiogenesis: additive insults that may lead to preeclampsia. Hypertension 2004;43:988-992.
130. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672-683.
131. Thadhani R, Mutter WP, Wolf M, Levine RJ, Taylor RN, Sukhatme VP, Ecker J, Karumanchi SA. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 2004;89:770-775.
132. Bdolah Y, Karumanchi SA, Sachs BP. Recent advances in understanding of preeclampsia. Croat Med J 2005;46:728-736.
133. Lam C, Lim KH, Karumanchi SA. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension 2005;46:1077-1085.
134. Nadar SK, Karalis I, Al Yemeni E, Blann AD, Lip GY. Plasma markers of angiogenesis in pregnancy induced hypertension. Thromb Haemost 2005;94:1071-1076.
135. Maynard SE, Venkatesha S, Thadhani R, Karumanchi SA. Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia. Pediatr Res 2005;57:1R-7R.
136. Rajakumar A, Michael HM, Rajakumar PA, Shibata E, Hubel CA, Karumanchi SA, Thadhani R, Wolf M, Harger G, Markovic N. Extra-placental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women. Placenta 2005;26:563-573.
137. Levine RJ, Thadhani R, Qian C, Lam C, Lim KH, Yu KF, Blink AL, Sachs BP, Epstein FH, Sibai BM, et al. Urinary placental growth factor and risk of preeclampsia. JAMA 2005;293:77-85.
138. Levine RJ, Karumanchi SA. Circulating angiogenic factors in preeclampsia. Clin Obstet Gynecol 2005;48:372-386.
139. Aggarwal PK, Jain V, Sakhuja V, Karumanchi SA, Jha V. Low urinary placental growth factor is a marker of preeclampsia. Kidney Int 2006;69:621-624.
140. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:992-1005.
141. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006;12:642-649.
142. Levine RJ, Qian C, Maynard SE, Yu KF, Epstein FH, Karumanchi SA. Serum sFlt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women. Am J Obstet Gynecol 2006;194:1034-1041.
143. Tjoa ML, Levine RJ, Karumanchi SA. Angiogenic factors and preeclampsia. Front Biosci 2007;12:2395-2402.